WO2003052094A2 - Expressionsvektor zur herstellung von annexin v - Google Patents
Expressionsvektor zur herstellung von annexin v Download PDFInfo
- Publication number
- WO2003052094A2 WO2003052094A2 PCT/EP2002/014347 EP0214347W WO03052094A2 WO 2003052094 A2 WO2003052094 A2 WO 2003052094A2 EP 0214347 W EP0214347 W EP 0214347W WO 03052094 A2 WO03052094 A2 WO 03052094A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression vector
- vector
- annexin
- expression
- gene
- Prior art date
Links
- 239000013604 expression vector Substances 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title description 4
- 108050008874 Annexin Proteins 0.000 title description 3
- 102000000412 Annexin Human genes 0.000 title description 2
- 239000013598 vector Substances 0.000 claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 108090000672 Annexin A5 Proteins 0.000 claims abstract description 53
- 102000004121 Annexin A5 Human genes 0.000 claims abstract description 46
- 229930027917 kanamycin Natural products 0.000 claims abstract description 31
- 229960000318 kanamycin Drugs 0.000 claims abstract description 31
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims abstract description 31
- 229930182823 kanamycin A Natural products 0.000 claims abstract description 31
- 238000010367 cloning Methods 0.000 claims abstract description 25
- 238000013518 transcription Methods 0.000 claims abstract description 18
- 230000035897 transcription Effects 0.000 claims abstract description 18
- 230000027455 binding Effects 0.000 claims abstract description 17
- 230000010076 replication Effects 0.000 claims abstract description 9
- 241000588724 Escherichia coli Species 0.000 claims description 31
- 108091008146 restriction endonucleases Proteins 0.000 claims description 21
- 108020004705 Codon Proteins 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 claims description 13
- 229960000723 ampicillin Drugs 0.000 claims description 13
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 12
- 241000287828 Gallus gallus Species 0.000 claims description 8
- 108010054278 Lac Repressors Proteins 0.000 claims description 7
- 239000004098 Tetracycline Substances 0.000 claims description 7
- 235000019364 tetracycline Nutrition 0.000 claims description 7
- 150000003522 tetracyclines Chemical class 0.000 claims description 7
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 101150017040 I gene Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101000780124 Gallus gallus Annexin A5 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004154 Annexin A6 Human genes 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- DLRVVLDZNNYCBX-CAPXFGMSSA-N allolactose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)O1 DLRVVLDZNNYCBX-CAPXFGMSSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 101150078341 rop gene Proteins 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02787950A EP1456387A2 (de) | 2001-12-18 | 2002-12-16 | Expressionsvektor zur herstellung von annexin v |
AU2002352251A AU2002352251A1 (en) | 2001-12-18 | 2002-12-16 | Expression vector for the production of annexin v |
US10/499,282 US20050142657A1 (en) | 2001-12-18 | 2002-12-16 | Expression vector for the production of annexin v |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10162434.4 | 2001-12-18 | ||
DE10162434A DE10162434A1 (de) | 2001-12-18 | 2001-12-18 | Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003052094A2 true WO2003052094A2 (de) | 2003-06-26 |
WO2003052094A3 WO2003052094A3 (de) | 2004-03-04 |
Family
ID=7709833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/014347 WO2003052094A2 (de) | 2001-12-18 | 2002-12-16 | Expressionsvektor zur herstellung von annexin v |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050142657A1 (de) |
EP (1) | EP1456387A2 (de) |
AU (1) | AU2002352251A1 (de) |
DE (1) | DE10162434A1 (de) |
HU (1) | HUP0200682A2 (de) |
WO (1) | WO2003052094A2 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
US20090291086A1 (en) * | 2001-02-21 | 2009-11-26 | Alavita Pharmaceuticals, Inc. | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia |
US7645739B2 (en) * | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
US20050222030A1 (en) * | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
US7635680B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073332A1 (en) * | 1999-06-01 | 2000-12-07 | University Of Washington | Annexin derivatives with endogenous chelation sites |
WO2003022883A2 (de) * | 2001-09-13 | 2003-03-20 | Responsif Gmbh | Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3710364A1 (de) * | 1987-03-28 | 1989-01-19 | Boehringer Ingelheim Int | Vascular-antikoagulierende proteine, dna die diese kodieren, verfahren zu deren herstellung sowie deren verwendung |
JP2701047B2 (ja) * | 1988-07-21 | 1998-01-21 | 興和株式会社 | 抗血液凝固作用を有するポリペプチド |
ES2045669T3 (es) * | 1989-07-15 | 1994-01-16 | Boehringer Ingelheim Int | Procedimiento para la purificacion de anexinas. |
US6368603B1 (en) * | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
US6010705A (en) * | 1997-04-11 | 2000-01-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Attenuated, invasive vaccines against fish pathogens |
ES2286247T3 (es) * | 2001-02-21 | 2007-12-01 | Alavita Pharmaceuticals, Inc. | Proteinas anexinicas modificacdas y tratamiento de la trombosis. |
-
2001
- 2001-12-18 DE DE10162434A patent/DE10162434A1/de not_active Withdrawn
-
2002
- 2002-02-21 HU HU0200682A patent/HUP0200682A2/hu unknown
- 2002-12-16 US US10/499,282 patent/US20050142657A1/en not_active Abandoned
- 2002-12-16 AU AU2002352251A patent/AU2002352251A1/en not_active Abandoned
- 2002-12-16 EP EP02787950A patent/EP1456387A2/de not_active Withdrawn
- 2002-12-16 WO PCT/EP2002/014347 patent/WO2003052094A2/de not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073332A1 (en) * | 1999-06-01 | 2000-12-07 | University Of Washington | Annexin derivatives with endogenous chelation sites |
WO2003022883A2 (de) * | 2001-09-13 | 2003-03-20 | Responsif Gmbh | Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems |
Non-Patent Citations (3)
Title |
---|
TAIT J F ET AL: "SITE-SPECIFIC MUTAGENESIS OF ANNEXIN V ROLE OF RESIDUES FROM ARG-200 TO LYS-207 IN PHOSPHOLIPID BINDING" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, Bd. 288, Nr. 1, 1991, Seiten 141-144, XP009015380 ISSN: 0003-9861 * |
TURNAY JAVIER ET AL: "Collagen binding activity of recombinant and N-terminally modified annexin V (Anchorin CII)." JOURNAL OF CELLULAR BIOCHEMISTRY, Bd. 58, Nr. 2, 1995, Seiten 208-220, XP009015379 ISSN: 0730-2312 in der Anmeldung erw{hnt * |
ZHANG L N ET AL: "Expression and purification of recombinant human annexin V in Escherichia coli." PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, Bd. 30, Nr. 4, November 2000 (2000-11), Seiten 305-312, XP009015378 ISSN: 1082-6068 * |
Also Published As
Publication number | Publication date |
---|---|
HU0200682D0 (en) | 2002-04-29 |
AU2002352251A1 (en) | 2003-06-30 |
AU2002352251A8 (en) | 2003-06-30 |
US20050142657A1 (en) | 2005-06-30 |
HUP0200682A2 (hu) | 2003-11-28 |
WO2003052094A3 (de) | 2004-03-04 |
EP1456387A2 (de) | 2004-09-15 |
DE10162434A1 (de) | 2003-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0099084B1 (de) | Verfahren zur Herstellung von Interferon und Expressionsvektoren dafür | |
EP0759997B1 (de) | Verwendung des tetracyclinpromotors zur stringent regulierten produktion von rekombinanten proteinen in prokaryontischen zellen | |
DE19631919C2 (de) | Anti-Sinn-RNA mit Sekundärstruktur | |
DE3111405C2 (de) | ||
DE69920113T2 (de) | Escherichia coli Wirt/Vektorsystem basierend auf einer antibiotikafreien Selektion durch Komplementation einer Auxotrophie | |
DD209476A5 (de) | Verfahren zur stabilisierung und selektierung von wirtszellen, die rekombinierende dna enthalten | |
DD229427A5 (de) | Verfahren zur gewinnung eines polypeptids | |
DD212267A5 (de) | Verfahren zur herstellung einer fuer rinderwachstumshormon kodierenden desoxynucleotid-sequenz | |
DD212982A5 (de) | Verfahren zur herstellung von rinder-wachstumshormon-aehnlichen polypeptiden | |
DD212748A5 (de) | Verfahren zur bildung doppelstraengiger, hybride human-leukozyten-interferone kodierender dns | |
DD216044A5 (de) | Verfahren zur herstellung eines rekombinierenden dna-klonierungsvektors | |
EP0288809A1 (de) | Bifunktionelle Proteine | |
DE102009011253B3 (de) | Selektion kodierender Nukleinsäure-Konstrukte auf Abwesenheit von Frameshift-Mutationen | |
EP0460673A1 (de) | Rekombinantes Restriktionsenzym Sau3AI kodierendes DNS | |
WO2003052094A2 (de) | Expressionsvektor zur herstellung von annexin v | |
DE69532646T2 (de) | Verfahren zur herstellung extrazellulärer proteine in bakterien | |
EP0291021A2 (de) | Für ein lytisch wirksames, chimäres Protein kodierende rekombinante DNA und ihre Verwendung | |
DE20221079U1 (de) | Expressionsvektor zur Herstellung von Annexin V | |
DE3226515A1 (de) | Expressionsvektoren | |
EP0345615A2 (de) | Expressionsvektoren zur Herstellung unfusionierter Proteine in Mikroorganismen | |
EP0190652B1 (de) | Gene für biologisch aktive Proteine | |
DE3431023C2 (de) | ||
DD202451A5 (de) | Verfahren zur herstellung eines dna transfervektors, der eine ein somatostatin oder einen somatostatinvorlaeufer codierende nukleotidsequenz enthaelt | |
DE60225366T2 (de) | Expressionskontrollsequenz | |
DE69635178T2 (de) | Ein bei der Expression von Nitrilase-Gen beteiligter regularischer Faktor, sowie dessen Gen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002787950 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002787950 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10499282 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002787950 Country of ref document: EP |